Hostname: page-component-cc8bf7c57-qfg88 Total loading time: 0 Render date: 2024-12-11T04:59:42.900Z Has data issue: false hasContentIssue false

EPA-1240 – Sexual Dysfunction and Antidepressant Medications in Male Depressed Patients

Published online by Cambridge University Press:  15 April 2020

D. Karaiskos
Affiliation:
Psychiatry, Eginition Hospital of Athens, Athens, Greece
E. Tzavellas
Affiliation:
Psychiatry, Eginition Hospital of Athens, Athens, Greece
I. Elias
Affiliation:
Endocrinology, Elena Venizelou Hospital, Athens, Greece
I. Liappas
Affiliation:
Psychiatry, Eginition Hospital of Athens, Athens, Greece
A. Liappas
Affiliation:
Pharmacology, University of Athens School of Medicine, Athens, Greece
T. Paparrigopoulos
Affiliation:
Psychiatry, Eginition Hospital of Athens, Athens, Greece

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction:

Sexual dysfunction, such as low libido, erectile dysfunction and anorgasmia, is very common in patients taking serotoninergic antidepressants (SSRIs). These adverse effects persist throughout the treatment period, are not self-limited, and drive many male patients to treatment discontinuation in order to recuperate normal sexual functioning.

Objectives - Aims:

The purpose of the present study was to investigate the sexual function of male patients treated with antidepressants for major depression, before initiation of treatment, during treatment and two months following withdrawal of SSRIs.

Methods:

This observational study comprised 25 male patients (age: 30–50 years) followed-up on an outpatient basis for major depression.

Sexual functioning was assessed with the Arizona Sexual Experience Scale (ASEX) and depressive symptoms with the Hamilton Rating Scale for Depression (HDRS) at three time points: baseline (period free of medication), three months after starting treatment with SSRIs, and two months following antidepressant discontinuation.

Paired samples t-tests were used for comparisons between numeric variables at the three time points and Spearman's correlation coefficients were calculated between factors associated with sexual dysfunction.

Results:

Mean values ??(± SD) of ASEX and HDRS scores at the initial, second and final assessment are shown in Table 1.

 Initial assessmentSecond assessmentFinal assessment
ASEX17.8± 5.425.6±7.9*12.9±5.8**
HDRS22.3±4.24.2±3.4*7.3±5.2**

Correlation coefficients between ASEX, HDRS and age at the three points of evaluation are presented in Table 2.

ASEX 1 Spearman's rho Sig. (2-tailed) ASEX 2 Spearman's rho Sig. (2-tailed)  ASEX 3 Spearman's rho Sig. (2-tailed)
HDRS 1 0.775 <0.05HDRS 20.3180.340HDRS 30,719<0,005 
Age0.842<0.05Age0.5540.062Age0.856<0.05

Conclusions:

Antidepressants (SSRIs) have a negative impact on sexual functioning of male depressed patients. Quality of sexual functioning is negatively associated with age and the severity of depressive symptoms before the administration of antidepressant treatment. Sexual functioning significantly improves after discontinuation of antidepressants; this improvement is even superior to the pre-treatment period of sexual functioning.

Type
E02 - e-Poster Oral Session 02: Depression and Suicide
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.